Revitalising Small Molecule Therapeutics
Establishing a flawless physicochemical foundation to definitively dictate downstream scalability, stability, and clinical success.
The Cost of Incomplete Characterisation
The vast majority of modern small molecules fail not due to a lack of efficacy, but due to insurmountable biopharmaceutical barriers. Unanticipated polymorphic shifts, severe solubility limitations, and unstable salt forms frequently derail development timelines. When sponsors rush an Active Pharmaceutical Ingredient (API) into formulation without rigorous physicochemical profiling, they risk catastrophic late-stage failures and massive financial burn during clinical scale-up.
Strategic Physicochemical Profiling
We do not simply accept a raw molecule; we aggressively interrogate its behaviour. As your technical co-architects, Dhee Lifesciences engineers a bespoke pre-formulation strategy. We conduct exhaustive solid-state characterisation, salt and cocrystal screening, and polymorph evaluation. By mapping the molecule’s pKa, log P, and precise degradation pathways early, we engineer around physical limitations and lock in a highly stable, developable asset ready for complex formulation.
Accelerated by the SynapTx™ AI Ecosystem
Predicting physical behaviour before bench execution. By feeding proprietary molecular structures into our sovereign SynapTx™ engine, we can instantly parse decades of complex pharmacological literature and historical scaffold data. The AI highlights non-obvious degradation risks and predicts optimal salt forms mathematically, providing our scientists with a heavily referenced, data-backed foundation for API selection.